Novo Nordisk Faces Critical Juncture Amid Legal and Competitive Pressures

The year 2025 is shaping up to be a formidable challenge for Novo Nordisk, with its share price having plummeted by more than half and its once-dominant market position showing signs of erosion. Recent developments, including a pivotal court ruling in India and new strategic plans for its next-generation drug candidate CagriSema, are introducing fresh volatility. Investors are now questioning whether these moves can finally establish a floor for the beleaguered stock or if generic competition is poised to deliver another significant blow.

Share Performance Under Severe Pressure

The latest news arrives against a backdrop of extreme weakness for Novo Nordisk’s equity. The stock remains locked in a powerful downtrend, having lost over 52% of its value since the start of the year. This sell-off is attributed to a confluence of negative factors:

• Clinical Setbacks: The failure of a key Alzheimer’s disease study in late November dealt a heavy blow to investor sentiment.
• Intensifying Rivalry: Competitor Eli Lilly has cut prices for its weight-loss drug Zepbound in the United States, applying direct commercial pressure and forcing a response.
• Cost-Cutting Measures: In reaction to the ongoing crisis, management has announced a “strategic reset,” which reports suggest could lead to the elimination of up to 9,000 positions globally.

This context makes the approaching “generic cliff” a more immediate threat, heightening the urgency for the pharmaceutical giant’s strategic maneuvers.

A Partial Legal Victory in India

A recently upheld ruling from the Delhi High Court delivers a mixed message to anxious shareholders. In the patent dispute with Indian generic manufacturer Dr. Reddy’s, the outcome presented both positives and negatives for Novo Nordisk. The court has permitted the competitor to manufacture and export semaglutid—the active ingredient behind blockbuster drugs Ozempic and Wegovy—to countries where patent protection is not in force.

Should investors sell immediately? Or is it worth buying Novo Nordisk?

However, the Danish company successfully defended a crucial barrier. Dr. Reddy’s is prohibited from selling the drug in the fast-growing Indian domestic market until the patent expires in March 2026. This decision grants Novo Nordisk a critical 15-month reprieve to solidify its market position before lower-cost generic alternatives can flood this key region.

Pivoting to New Patient Demographics

To cushion the impending pressure on profit margins, the company’s product pipeline must deliver results. Novo Nordisk is now adopting an offensive strategy by expanding the potential market for its next-generation weight-loss candidate, CagriSema. According to current registry data, a Phase 3 clinical trial is set to commence in January 2026. This study will aim to evaluate the drug’s efficacy in children and adolescents aged 8 to 17.

This move carries substantial strategic weight. With earlier trial results in adults having partially failed to meet investors’ exceptionally high expectations, targeting younger patient groups is intended to unlock new growth potential and clearly differentiate the medication from rival products such as Eli Lilly’s Zepbound.

The short-term export allowance for Dr. Reddy’s serves as a stark warning that Novo Nordisk must accelerate its transition to new therapies like CagriSema to support its valuation. All eyes are now on upcoming quarterly results to assess whether the painful restructuring efforts are beginning to yield tangible benefits.